Exact Sciences: ASCO Urges Breast Recurrence Score Test in Node-Negative, Most Node-Positive Early Breast Cancer

 

• Oncotype DX^® receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation
• New guidelines reflect highest level of evidence from independent RxPONDER study, recently published in The New England Journal of Medicine

https://www.biospace.com/article/releases/updated-asco-guidelines-strongly-recommend-use-of-the-oncotype-dx-breast-recurrence-score-test-in-node-negative-and-the-majority-of-node-positive-early-stage-breast-cancer-patients/